PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma
Class Ia Phosphatidylinositol 3-Kinase
In this single-group study, idelalisib showed antitumor activity with an acceptable safety profile in patients with indolent non-Hodgkin's lymphoma who had received extensive prior treatment. (Funded by Gilead Sciences and others; ClinicalTrials.gov number, NCT01282424.).